Benefits
Antibiotic-associated diarrhea prevention
Multiple meta-analyses including a 2015 Cochrane review confirm S. boulardii significantly reduces antibiotic-associated diarrhea (AAD) incidence by approximately 50% in adults and children. Unique advantage: yeast is naturally resistant to antibacterial antibiotics, so it can be taken concurrently. Standard dose is 250 mg twice daily during and 1–2 weeks after antibiotic therapy.
Clostridioides difficile recurrence prevention
A Cochrane review of 31 randomized trials (8,672 patients) found probiotics, including S. boulardii, reduced C. difficile-associated diarrhea by about 60 percent (RR 0.40) when given alongside antibiotics, with the clearest benefit in patients at higher baseline risk. S. boulardii's own effect reached significance in children but was not clearly established in adults. It is used as an adjunct during vancomycin or fidaxomicin therapy, where the usual recurrence rate is 20 to 30 percent. Mechanism includes degradation of C. difficile toxins A and B by a 54-kDa serine protease.
Acute pediatric gastroenteritis
ESPGHAN-recommended probiotic for acute pediatric gastroenteritis (AGE). Multiple RCTs and meta-analyses show 250–750 mg/day for 5–7 days reduces diarrhea duration by approximately 1 day in children. Particularly effective for rotavirus-induced AGE.
Traveler's diarrhea prevention
Multiple RCTs show S. boulardii (250–1,000 mg/day starting 5 days before travel) reduces traveler's diarrhea incidence by 21–35% depending on destination. Effect is dose-dependent and most consistent at higher doses (1 g/day). Considered a first-line non-antibiotic option per ISTM travel medicine guidelines.
Helicobacter pylori eradication adjunct
When added to standard triple therapy (PPI + clarithromycin + amoxicillin), S. boulardii modestly increases H. pylori eradication rates (about 9 percent relative improvement, risk ratio 1.09) and cuts therapy-related side effects, especially diarrhea, by roughly half. It is noted as an adjunct in Maastricht VI/Florence Consensus guidance for H. pylori management.
Mechanism of action
Antibiotic resistance enabling concurrent use
As a yeast (eukaryote), S. boulardii is naturally insensitive to all antibacterial antibiotics. This allows concurrent administration during antibacterial therapy without losing viability — a crucial advantage over bacterial probiotics that are killed by the same antibiotics they're meant to mitigate.
Toxin neutralization
S. boulardii secretes a 54-kDa serine protease that degrades C. difficile toxins A and B and a 120-kDa protein that interferes with cholera toxin action. It also produces phosphatases that degrade endotoxins (LPS) and a 63-kDa protein that inhibits cholera toxin's cAMP elevation in enterocytes.
Trophic effects on intestinal mucosa
Stimulates intestinal brush border enzymes (lactase, sucrase, maltase) and increases intestinal IgA secretion. Enhances enterocyte recovery after damage from rotavirus, Cryptosporidium, or chemotherapy by stimulating epithelial migration and proliferation through polyamine production.
Immune modulation and inflammatory response regulation
Down-regulates pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) while increasing anti-inflammatory IL-10 and regulatory T-cells. Inhibits NF-κB and MAPK signaling in inflammatory bowel disease models. Reduces neutrophil migration to inflamed gut tissue.
Pathogen exclusion via D-mannose mimicry
The yeast cell wall contains mannose residues that bind type-1 fimbriae of pathogenic E. coli (and other enteric bacteria), preventing their adhesion to intestinal epithelium and effectively neutralizing them via clearance with the yeast in stool.
Clinical trials
2019 Cochrane evidence review of 33 clinical trials evaluating multiple probiotics for AAD prevention in children.
Pediatric population. Pooled analysis.
S. boulardii at high doses (5-40 billion CFU/day) and LGG showed strongest, most consistent effects. S. boulardii reduced AAD risk substantially. Note: PLACIDE 2013 negative for elderly hospitalized; pediatric evidence stronger.
Cochrane systematic review and meta-analysis of 31 randomized trials (8,672 patients) of probiotics, including S. boulardii, given alongside antibiotics to prevent Clostridioides difficile-associated diarrhea.
31 randomized trials, adults and children taking antibiotics.
Probiotics as a class reduced C. difficile-associated diarrhea by about 60 percent (RR 0.40), with the clearest benefit in patients whose baseline risk exceeded 5 percent. S. boulardii's own effect reached significance in children but not clearly in adults. Evidence is modest, and for established recurrent infection modern options (fidaxomicin, bezlotoxumab, fecal microbiota transplantation) are better supported than probiotics.
Zhou et al. 2019 (Helicobacter) systematic review and meta-analysis with trial sequential analysis of 18 randomized trials of S. boulardii added to standard H. pylori eradication therapy.
18 randomized trials, 3,592 patients.
Across 18 randomized trials (3,592 patients), adding S. boulardii to standard eradication therapy modestly increased H. pylori eradication (RR 1.09, about 9 percent relative improvement) and reduced total side effects (RR 0.47) and diarrhea (RR 0.33). Reasonable adjunct.